Skip to main content
Start triage

Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Need urgent help? Start triage first, then route to emergency care.

Start symptom intake Emergency vets near you

Meds A-Z

Moxidectin

Detailed information about Moxidectin

Official label facts Owner quick guide first Marketing clearly labeled
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Add to My Pet's Meds

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Reviewed / Updated / Sources

Reviewed: Not available

Updated: February 12, 2026, 10:44 PM UTC

Sources:

Pet Owner Quick Guide

Start here first for the simple next-step summary.

Used for:

Credelio Quattro™ is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina ),...

What to watch for:

  • Use once-a-month in dogs at 8 weeks of age or older
  • QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only
  • This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result
  • Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions
  • Do not use in sick, debilitated, or underweight animals
  • Do not use in horses intended for human consumption
  • A withdrawal period has not been established for this product on preruminating calves
  • Do not use on calves to be processed for veal
  • Medication error NOS (1 reports)
  • Lack of efficacy - tapeworm (1 reports)
  • Lack of efficacy - hookworm (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?
Safety & side effects

What to watch:

  • Use once-a-month in dogs at 8 weeks of age or older
  • QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only
  • This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result
  • Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions
  • Do not use in sick, debilitated, or underweight animals

Most reported reactions:

  • Medication error NOS (1 reports)
  • Lack of efficacy (endoparasite) - tapeworm (1 reports)
  • Lack of efficacy (endoparasite) - hookworm (1 reports)

When to call your vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
Talk to a Vet / Find a Vet Near You Start Symptom Intake

Data freshness: source data appears current.

Latest refresh: Mar 21, 2026, 10:02 a.m.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 21, 2026, 10:02 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Mar 19, 2026, 10:06 AM UTC
Image coming soon
Moxidectin

Moxidectin

Drug type: Generic ingredient • Branded profile • FDA branded products available

Species: Both

Manufacturer: Elanco US Inc.

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Elanco US Inc.
Form: Chewable Tablets, Gel, Injectable Solution, Liquid (Solution), Microspheres, Solution
Identifiers:
ANADA: 200615 ANADA: 200638 ANADA: 200700 ANADA: 200701 ANADA: 200714 ANADA: 200716 ANADA: 200718 ANADA: 200721 ANADA: 200746 ANADA: 200788 ANADA: 200811 ANADA: 200818 NADA: 141051 NADA: 141087 NADA: 141099 NADA: 141189 NADA: 141216 NADA: 141220 NADA: 141247 NADA: 141251
Source metadata:

Warnings / Contraindications

Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.

  • High: Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
25
Serious reports
7
Species represented
2
Grouped by Body System
Digestive (1) · Loss of appetite Skin & allergy (6) · Localised itching, Localised hair loss, Hair loss NOS Neurologic (1) · Unsteady walking (ataxia) Behavior (2) · Biting -aggression, Behavioral disorder (unspecified) Effectiveness (4) · Lack of efficacy (endoparasite) - tapeworm, Lack of efficacy (endoparasite) - hookworm, Lack of efficacy (endoparasite) - heartworm Other (18) · Skin sore, Skin lesion NOS, Skin irritation
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Other 1 Dog 1
Effectiveness 1 Dog 1
Effectiveness 1 Dog 1
Effectiveness 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1
Other 1 Cat 1
Other 1 Cat 0

Species coverage: Cat (19) Dog (13)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Dog Non-serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Cat Non-serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Dog Non-serious - 1
Skin & allergy Cat Non-serious - 1
Skin & allergy Cat Non-serious - 1
Other Cat Non-serious - 1
Effectiveness Dog Serious - 1
Effectiveness Dog Serious - 1
Effectiveness Dog Serious - 1
Effectiveness Dog Non-serious - 1
Other Dog Serious - 1
Skin & allergy Cat Non-serious - 1
Other Cat Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Skin & allergy Cat Non-serious - 1
Behavior Cat Non-serious - 1
Behavior Cat Non-serious - 1
Neurologic Dog Unknown - -
Digestive Cat Unknown - -
Skin & allergy Cat Unknown - -
Skin & allergy Cat Unknown - -
Other Dog Unknown - -
Other Dog Unknown - -
Other Dog Unknown - -
Source metadata:

Documents

Owner handouts and official technical documents are grouped for faster access.

Owner handouts (0)
  • No owner handouts linked yet.
Official label / PI (6)
  • 141-099 · EA
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadEA/146
  • 141-099 · FONSI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFonsi/149
  • Final Version PROHEART6 N141189C0137.pdf · Labeling
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/891
  • Final Version PROHEART6 N141189C0137.pdf · Labeling
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadLabeling/892
  • 141-220 · EA
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadEA/147
  • 141-220 · FONSI
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/document/downloadFonsi/150
SPL (27)
  • Credelio Quattro™ · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/16306/Credelio%20Quattro%E2%84%A2
  • BRAVECTO® PLUS · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/7989/BRAVECTO%C2%AE%20PLUS
  • NexGard® PLUS · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/14516/NexGard%C2%AE%20PLUS
  • Credelio Quattro™-CA1 · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/18151/Credelio%20Quattro%E2%84%A2-CA1
  • PARASEDGE® Multi for Dogs · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/10973/PARASEDGE%C2%AE%20Multi%20for%20Dogs
  • Barrier® for cats · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/11695/Barrier%C2%AE%20for%20cats
  • MoxiCloprid™ for Dogs · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/17608/MoxiCloprid%E2%84%A2%20for%20Dogs
  • Simparica TRIO® · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/8450/Simparica%20TRIO%C2%AE
  • Barrier® for dogs · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/12057/Barrier%C2%AE%20for%20dogs
  • MoxiCloprid™ for Cats · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/16987/MoxiCloprid%E2%84%A2%20for%20Cats
  • MoxiSolv™ Injection · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/15886/MoxiSolv%E2%84%A2%20Injection
  • PARASEDGE™ Multi for Cats · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/10974/PARASEDGE%E2%84%A2%20Multi%20for%20Cats
  • Midamox® for Cats · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/12237/Midamox%C2%AE%20for%20Cats
  • Quest® Gel · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1198/Quest%C2%AE%20Gel
  • Quest® Plus Gel · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/491/Quest%C2%AE%20Plus%20Gel
  • Midamox® for Dogs · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/12017/Midamox%C2%AE%20for%20Dogs
  • Tauramox™ · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/13895/Tauramox%E2%84%A2
  • Advantage Multi™ for Dogs · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/181/Advantage%20Multi%E2%84%A2%20for%20Dogs
  • advantage multi™ for cats · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/182/advantage%20multi%E2%84%A2%20for%20cats
  • Cydectin™ (moxidectin) Pour-On for Beef and Dairy Cattle · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1372/Cydectin%E2%84%A2%20%28moxidectin%29%20Pour-On%20for%20Beef%20and%20Dairy%20Cattle
  • ProHeart® 6 · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/244/ProHeart%C2%AE%206
  • Cydectin® Oral Drench for Sheep · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/101/Cydectin%C2%AE%20Oral%20Drench%20for%20Sheep
  • IMOXI™ Topical Solution for Cats · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/9090/IMOXI%E2%84%A2%20Topical%20Solution%20for%20Cats
  • IMOXI™ Topical Solution for Dogs · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/8109/IMOXI%E2%84%A2%20Topical%20Solution%20for%20Dogs
  • ProHeart™ · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/1220/ProHeart%E2%84%A2
  • Cydectin® · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/503/Cydectin%C2%AE
  • CORAXIS™ · SPL
    https://animaldrugsatfda.fda.gov/adafda/app/search/public/spl/file/2272/CORAXIS%E2%84%A2
FOI (53)
Source metadata:
Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Medication catalog: Source Roxee | Refreshed Feb 12, 2026, 10:44 PM UTC
  • Animal Drugs @ FDA: Source FDA | Refreshed Mar 21, 2026, 10:00 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Mar 21, 2026, 10:01 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Mar 21, 2026, 10:02 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Mar 19, 2026, 10:06 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Advantage Multi™ for Dogs BRAVECTO® PLUS Barrier® for cats Barrier® for dogs CORAXIS™ Credelio Quattro™ Credelio Quattro™-CA1 Cydectin® Cydectin® Oral Drench for Sheep Cydectin™ (moxidectin) Pour-On for Beef and Dairy Cattle IMOXI™ Topical Solution for Cats IMOXI™ Topical Solution for Dogs Midamox® for Cats Midamox® for Dogs MoxiCloprid™ for Cats MoxiCloprid™ for Dogs MoxiSolv™ Injection NexGard® PLUS PARASEDGE® Multi for Dogs PARASEDGE™ Multi for Cats ProHeart® 6 ProHeart™ Quest® Gel Quest® Plus Gel Simparica TRIO® Tauramox™ advantage multi™ for cats
Case-reported brands (openFDA): MSK
Catalog species: Both • FDA-labeled species: Beef, Beef And Non-Lactating Dairy, Calves, Cat, Dairy, Dog, Horse, No Use Class Stated Or Implied, Pony, Sheep
Rx/OTC: OTC, RX
Form/route: Chewable Tablets, Gel, Injectable Solution, Liquid (Solution), Microspheres, Solution, Tablet, Topical Solution • Oral, Subcutaneous, Topical, Transdermal
Applications: NADA 141-581 • NADA 141-518 • NADA 141-554 • NADA 141-619 • ANADA 200-700 • ANADA 200-714 • ANADA 200-818 • NADA 141-521 • ANADA 200-718 • ANADA 200-811 • ANADA 200-788 • ANADA 200-701 • ANADA 200-721 • NADA 141-087 • NADA 141-216 • ANADA 200-716 • ANADA 200-746 • NADA 141-251 • NADA 141-254 • NADA 141-099 • NADA 141-189 • NADA 141-247 • ANADA 200-638 • ANADA 200-615 • NADA 141-051 • NADA 141-220 • NADA 141-417
Documents: 59 (FOI: 53) • SPL: 27 • Label highlights • Official documents
Safety (openFDA)
Top reactions: Dog 24 • Cat 17 • View
Case summaries: 15 (showing 8) • View
openFDA reports are unverified and do not prove causation.
Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95), Fda_Label (0.95)
Diagnosis Codes
ICD10_CM: B74.8 ICD10_CM: B82.9 ICD10_CM: B86 ICD10_CM: B88.1
Other filariases

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal. (Contraindication, High)
Top reaction signals
Medication error NOS (1) Lack of efficacy (endoparasite) - tapeworm (1) Lack of efficacy (endoparasite) - hookworm (1) Lack of efficacy (endoparasite) - heartworm (1) Intentional misuse (1) Diabetes (1) Death (1) Skin sore (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
ANADA: 200615 ANADA: 200638 ANADA: 200700 ANADA: 200701 ANADA: 200714 ANADA: 200716 ANADA: 200718 ANADA: 200721 ANADA: 200746 ANADA: 200788 ANADA: 200811 ANADA: 200818 NADA: 141051 NADA: 141087 NADA: 141099 NADA: 141189 NADA: 141216 NADA: 141220 NADA: 141247 NADA: 141251 NADA: 141254 NADA: 141417 NADA: 141518 NADA: 141521
Package NDC Product NDC Form / Route Status
0010-4260-01 0010 -
0010-4260-02 0010 -
0010-4260-03 0010 -
0010-4261-01 0010 -
0010-4261-02 0010 -
0010-4261-03 0010 -
0010-4262-01 0010 -
0010-4262-02 0010 -
0010-4262-03 0010 -
0010-4263-01 0010 -
0010-4263-02 0010 -
0010-4263-03 0010 -
0010-4264-01 0010 -
0010-4264-02 0010 -
0010-4264-03 0010 -
0061-5996-01 0061 -
0061-5997-01 0061 -
0061-5998-01 0061 -
17030-023-01 17030 -
17030-023-03 17030 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 58 Clinical 0 Manufacturer 0 Marketing 0
Current Field Facts
  • contraindications: Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral… (Official, 2026-02-12)
  • side_effects: Top reported reactions (openFDA): Lack of efficacy (endoparasite) - heartworm, Vomiting, Lack of efficacy (endoparasite) - hookworm, Lethargy (see also Central… (Official, 2026-02-12)
  • usage: To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease. For the treatment and control of t… (Official, 2026-02-12)
Recent Revisions
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Credelio Quattro™
RX
Lotilaner Moxidectin Praziquantel Pyrantel Pamoate
Chewable Tablets • Oral
Label highlights
Official documents
Elanco US Inc. NADA 141-581 Approved Mar 9, 2026
BRAVECTO® PLUS
RX
Fluralaner Moxidectin
Solution • Topical
Label highlights
Official documents
Intervet, Inc. NADA 141-518 Approved Feb 2, 2026
NexGard® PLUS
RX
Afoxolaner Moxidectin Pyrantel Pamoate
Chewable Tablets • Oral
Label highlights
Official documents
Boehringer lngelheim Animal Health USA, Inc. NADA 141-554 Approved Feb 2, 2026
Credelio Quattro™-CA1
RX
Lotilaner Moxidectin Praziquantel Pyrantel Pamoate
Chewable Tablets • Oral
Label highlights
Official documents
Elanco US Inc. NADA 141-619 Approved Jan 5, 2026
PARASEDGE® Multi for Dogs
RX
Imidacloprid Moxidectin
Topical Solution • Topical
Label highlights
Official documents
Virbac AH, Inc. ANADA 200-700 Approved Dec 16, 2025
Barrier® for cats
RX
Imidacloprid Moxidectin
Topical Solution • Topical
Label highlights
Official documents
Aurora Pharmaceutical, Inc. ANADA 200-714 Approved Dec 5, 2025
MoxiCloprid™ for Dogs
RX
Imidacloprid Moxidectin
Topical Solution • Topical
Label highlights
Official documents
Bimeda Animal Health Limited ANADA 200-818 Approved Aug 28, 2025
Simparica TRIO®
RX
Moxidectin Pyrantel Pamoate Sarolaner
Chewable Tablets • Oral
Label highlights
Official documents
Zoetis Inc. NADA 141-521 Approved Jun 3, 2025
Barrier® for dogs
RX
Imidacloprid Moxidectin
Topical Solution • Topical
Label highlights
Official documents
Aurora Pharmaceutical, Inc. ANADA 200-718 Approved Jun 2, 2025
MoxiCloprid™ for Cats
RX
Imidacloprid Moxidectin
Topical Solution • Topical
Label highlights
Official documents
Bimeda Animal Health Limited ANADA 200-811 Approved Mar 28, 2025
MoxiSolv™ Injection
OTC
Moxidectin
Injectable Solution • Subcutaneous
Label highlights
Official documents
Bimeda Animal Health Limited ANADA 200-788 Approved Aug 1, 2024
PARASEDGE™ Multi for Cats
RX
Imidacloprid Moxidectin
Topical Solution • Topical
Label highlights
Official documents
Virbac AH, Inc. ANADA 200-701 Approved Oct 24, 2023
Midamox® for Cats
RX
Imidacloprid Moxidectin
Topical Solution • Topical
Label highlights
Official documents
Norbrook Laboratories, Ltd. ANADA 200-721 Approved Oct 10, 2023
Quest® Gel
OTC
Moxidectin
Gel • Oral
Label highlights
Official documents
Zoetis Inc. NADA 141-087 Approved Sep 19, 2023
Quest® Plus Gel
OTC
Moxidectin Praziquantel
Gel • Oral
Label highlights
Official documents
Zoetis Inc. NADA 141-216 Approved Sep 19, 2023
Midamox® for Dogs
RX
Imidacloprid Moxidectin
Topical Solution • Topical
Label highlights
Official documents
Norbrook Laboratories, Ltd. ANADA 200-716 Approved Aug 23, 2023
Tauramox™
OTC
Moxidectin
Injectable Solution • Subcutaneous
Label highlights
Official documents
Norbrook Laboratories, Ltd. ANADA 200-746 Approved Apr 3, 2023
Advantage Multi™ for Dogs
RX
Imidacloprid Moxidectin
Liquid (Solution) • Topical
Label highlights
Official documents
Elanco US Inc. NADA 141-251 Approved Feb 2, 2023
advantage multi™ for cats
RX
Imidacloprid Moxidectin
Solution • Topical
Label highlights
Official documents
Elanco US Inc. NADA 141-254 Approved Aug 22, 2022
Cydectin™ (moxidectin) Pour-On for Beef and Dairy Cattle
OTC
Moxidectin
Solution • Transdermal
Label highlights
Official documents
Elanco US Inc. NADA 141-099 Approved Jun 8, 2022
ProHeart® 6
RX
Moxidectin
Microspheres • Subcutaneous
Label highlights
Official documents
Zoetis Inc. NADA 141-189 Approved May 17, 2021
Cydectin® Oral Drench for Sheep
OTC
Moxidectin
Liquid (Solution) • Oral
Label highlights
Official documents
Elanco US Inc. NADA 141-247 Approved Jan 12, 2021
IMOXI™ Topical Solution for Cats
RX
Imidacloprid Moxidectin
Topical Solution • Topical
Label highlights
Official documents
Vetoquinol USA, Inc. ANADA 200-638 Approved Jun 1, 2020
IMOXI™ Topical Solution for Dogs
RX
Imidacloprid Moxidectin
Topical Solution • Topical
Label highlights
Official documents
Vetoquinol USA, Inc. ANADA 200-615 Approved Dec 30, 2019
ProHeart™
RX
Moxidectin
Tablet • Oral
Label highlights
Official documents
Zoetis Inc. NADA 141-051 Approved Jun 18, 2018
Cydectin®
OTC
Moxidectin
Liquid (Solution) • Subcutaneous
Label highlights
Official documents
Elanco US Inc. NADA 141-220 Approved Dec 18, 2017
CORAXIS™
RX
Moxidectin
Solution • Topical
Label highlights
Official documents
Elanco US Inc. NADA 141-417 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Composition / specifications
56.25 mg lotilaner, 0.056 mg moxidectin, 14.25 mg praziquantel, and 14.25 mg pyrantel; 112.5 mg lotilaner, 0.113 mg moxidectin, 28.5 mg praziquantel, and 28.5 mg pyrantel; 225 mg lotilaner, 0.225 mg moxidectin, 57 mg praziquantel, and 57 mg pyrantel; 450 mg lotilaner, 0.45 mg moxidectin, 114 mg praziquantel, and 114 mg pyrantel; 900 mg lotilaner, 0.9 mg moxidectin, 228 mg praziquantel, and 228 mg pyrantel
Dogs
Indication

Credelio Quattro™ is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina), hookworm (fourth stage larvae, immature adult, and adult Ancylostoma caninum and adult Uncinaria stenocephala), and tapeworm (Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus) infections. Credelio Quattro™ kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma Americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (longhorned tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater. Credelio Quattro™ is indicated for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.

Dosage

Administer orally once a month, at the minimum dosage of 9 mg/lb (20 mg/kg) lotilaner, 0.009 mg/lb (0.02 mg/kg) moxidectin, 2.28 mg/lb (5 mg/kg) praziquantel, and 2.28 mg/lb (5 mg/kg) pyrantel (as pamoate salt).

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Cat, No Use Class Stated Or Implied
Composition / specifications
Each milliliter contains 280 mg of fluralaner and 14 mg of moxidectin
Cats
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati; 4th stage larvae, immature adults and adults) and hookworm (Ancylostoma tubaeforme; 4th stage larvae, immature adults and adults). Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Ixodes scapularis (black-legged tick), Dermacentor variabilis (American dog tick), Haemaphysalis longicornis (Asian longhorned tick), and Amblyomma maculatum (Gulf Coast tick)] for 2 months in cats and kittens 6 months of age and older and weighing 2.6 lb or greater.

Dosage

Administer topically as a single dose every 2 months to provide a minimum dose of 18.2 mg/lb (40 mg/kg) fluralaner and 0.9 mg/lb (2 mg/kg) moxidectin.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each chewable tablet contains 9.375 mg afoxolaner, 45 mcg moxidectin, and 18.75 mg pyrantel; 18.75 mg afoxolaner, 90 mcg moxidectin, and 37.5 mg pyrantel; 37.5 mg afoxolaner, 180 mcg moxidectin, and 75 mg pyrantel; 75 mg afoxolaner, 360 mcg moxidectin, and 150 mg pyrantel; or 150 mg afoxolaner, 720 mcg moxidectin, and 300 mg pyrantel.
Dogs
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult hookworm (Ancylostoma caninum, Ancylostoma braziliense, and Uncinaria stenocephala) and roundworm (Toxocara canis and Toxascaris leonina) infections. Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of Ixodes scapularis (blacklegged tick), Rhipicephalus sanguineus (brown dog tick), Dermacentor variabilis (American dog tick), Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), and Haemaphysalis longicornis (longhorned tick) infestations for one month in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater. For the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.

Dosage

Administer orally once a month at the minimum dose of 1.14 mg/lb (2.5 mg/kg) afoxolaner, 5.45 mcg/lb (12 mcg/kg) moxidectin, and 2.27 mg/lb (5.0 mg/kg) pyrantel (as pamoate salt). For heartworm disease prevention, give once monthly for at least six months after last exposure to mosquitoes.

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications
Each chewable tablet contains: 56.25 mg lotilaner, 0.056 mg moxidectin, 14.25 mg praziquantel, and 14.25 mg pyrantel* 112.5 mg lotilaner, 0.113 mg moxidectin, 28.5 mg praziquantel, and 28.5 mg pyrantel* 225 mg lotilaner, 0.225 mg moxidectin, 57 mg praziquantel, and 57 mg pyrantel* 450 mg lotilaner, 0.45 mg moxidectin, 114 mg praziquantel, and 114 mg pyrantel* 900 mg lotilaner, 0.9 mg moxidectin, 228 mg praziquantel, and 228 mg pyrantel* *As pamoate salt
Dogs
Indication

For the treatment of infestations caused by New World screwworm (Cochliomyia hominivorax) larvae (myiasis) in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater.

Dosage

Administer orally at the minimum dosage of 9 mg/lb (20 mg/kg) lotilaner, 0.009 mg/lb (0.02 mg/kg) moxidectin, 2.28 mg/lb (5 mg/kg) praziquantel, and 2.28 mg/lb (5 mg/kg) pyrantel (as pamoate salt).

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
100 mg/mL (10%) imidacloprid and 25 mg/mL (2.5%) moxidectin
Dogs
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. It is also indicated for the treatment and control of the following intestinal parasites: adult, immature adult and fourth stage larvae in hookworm species (Ancylostoma caninum and Uncinaria stenocephala); adult and fourth stage larvae in roundworm species (Toxocara canis); and adult stage in roundworm species (Toxascaris leonina) and whipworm (Trichuris vulpis).

Dosage

The recommended minimum dose is 4.5 mg/lb. (10 mg/kg) imidacloprid and 1.1mg/lb. (2.5 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
10% imidacloprid and 1% moxidectin
Cats
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. For the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxocara cati).

Dosage

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.

Limitations
Ferrets
Indication

For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenophalides felis) and is indicated for the treatment of flea infestations on ferrets.

Dosage

The recommended minimum dose for a ferret is 9 m/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications
100 mg/mL (10%) imidacloprid and 25 mg/mL (2.5%) moxidectin
Dogs
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis; and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; and the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis); kills adult fleas and treats flea infestations (Ctenocephalides felis); treats and controls sarcoptic mange caused by Sarcoptes scabiei var. canis.

Dosage

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each chewable tablet contains either: 3.0 mg sarolaner / 0.06 mg moxidectin / 12.5 mg pyrantel (as pamoate salt), 6.0 mg sarolaner / 0.12 mg moxidectin / 25.0 mg pyrantel (as pamoate salt), 12.0 mg sarolaner / 0.24 mg moxidectin / 50.0 mg pyrantel (as pamoate salt), 24.0 mg sarolaner / 0.48 mg moxidectin / 100 mg pyrantel (as pamoate salt), 48.0 mg sarolaner / 0.96 mg moxidectin / 200 mg pyrantel (as pamoate salt) or 72.0 mg sarolaner / 1.44 mg moxidectin / 300 mg pyrantel (as pamoate salt)
Dogs
Indication

Simparica TRIO® is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina) and hookworm (L4, immature adult, and adult Ancylostoma caninum and adult Uncinaria stenocephala) infections. Simparica TRIO® kills adult fleas (Ctenocephalides felis) and is indicated for the treatment and prevention of flea infestations, the prevention of Dipylidium caninum (tapeworm) infections as a direct result of killing Ctenocephalides felis vector fleas on the treated dog, and the treatment and control of tick infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), and Haemaphysalis longicornis (Asian longhorned tick) for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater. Simparica TR O® is indicated for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.

Dosage

SimparicaTRIO® is given orally, once a month, at the recommended minimum dose of 0.54 mg/lb (1.2 mg/kg) sarolaner, 0.011 mg/lb (24 µg/kg) moxidectin, and 2.27 mg/lb (5 mg/kg) pyrantel (as pamoate salt).

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
10% (100 mg) imidacloprid and 2.5% (25 mg) moxidectin per milliliter
Dogs
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis); for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis; and for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).

Dosage

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Composition / specifications
100 mg/mL (10%) imidacloprid and 10 mg/mL (1%) moxidectin
Cats
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme).

Dosage

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.

Limitations
Ferrets
Indication

For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

Dosage

The recommended minimum dose is 9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Beef And Non-Lactating Dairy
Composition / specifications
10 mg moxidectin/mL
Beef and nonlactating dairy cattle
Indication

For the treatment and control of the following internal and external parasites of cattle:

Gastrointestinal Roundworms
Ostertagia ostertagi - Adults and L4 (including inhibited Larvae)
Haemonchus placei - Adults
Trichostrongylus axei - Adults and L4
Trichostrongylus colubriformis - Adults and L4
Cooperia oncophora - Adults
Cooperia pectinata - Adults
Cooperia punctata - Adults and L4
Cooperia spatulata - Adults
Cooperia surnabada - Adults and L4
Nematodirus helvetianus - Adults
Oesophagostomum radiatum - Adults and L4
Trichuris spp. - Adults

Lungworms
Dictyocaulus viviparus - Adults and L4

Cattle Grubs
Hypoderma bovis
Hypoderma lineatum

Mites
Psoroptes ovis
(Psoroptes communis var. bovis)

Lice
Linognathus vituli
Solenopotes capillatus

Persistent Activity
Moxidectin injectable has been proven to effectively protect cattle from reinfection with Dictyocaulus viviparus and Oesophagostomum radiatum for 42 days after treatment, Haemonchus placei for 35 days after treatment, and Ostertagia ostertagi and Trichostrongylus axei for 14 days after treatment.

Dosage

1 mL for each 110 lb (50 kg) body weight to provide 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
100 mg/mL (10%) imidacloprid and 10 mg/mL (1%) moxidectin
Cats
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancyclostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxacara cati).

Dosage

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 0.45 mg/lb (1 mg/kg) moxidectin, once a month, by topical administration.

Limitations
Ferrets
Indication

For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

Dosage

9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration. Only
the 0.4 mL applicator tube volume (PARASEDGE™ Multi 9) should be used on ferrets.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Cat, No Use Class Stated Or Implied
Composition / specifications
100 mg/mL (10%) imidacloprid and 10 mg/mL (1%) moxidectin
Cats
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme).

Dosage

The recommended minimum dose is 4.5 mg/lb (10.0 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month, by topical administration.

Limitations
Ferrets
Indication

For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

Dosage

The recommended minimum dose for a ferret is 9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2mg/kg) moxidectin, once a month, by topical administration. Only the 0.4 mL applicator volume (Midamox 9) should be used on ferrets.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Horse, Not For Meat Production • Pony, No Use Class Stated Or Implied
Composition / specifications
The gel contains 2 percent moxidectin (20 milligrams per milliliter).
Horses and Ponies (6 Months of Age and Older)
Indication

For the treatment and control of the following stages of gastrointestinal parasites in horses and ponies: Large Strongyles: Strongylus vulgaris: (adults and L4 / L5 arterial stages), Strongylus edentatus: (adults and tissue stages), Triodontophorus brevicauda: (adults), Triodontophorus serratus: (adults) Small Strongyles (adults): Cyathostomum spp., including Cyathostomum catinatum, Cyathostomum pateratum Cylicostephanus spp., including Cylicostephanus calicatus, Cylicostephanus goldi, Cylicostephanus longibursatus, Cylicostephanus minutus Cylicocyclus spp., including Cylicocyclus insigne, Cylicocyclus leptostomum, Cylicocyclus nassatus, Cylicocyclus radiatus Coronocyclus spp., including Coronocyclus coronatus, Coronocyclus labiatus, Coronocyclus labratus, Gyalocephalus capitatus, Petrovinema poculatus Small Strongyles: Undifferentiated lumenal larvae Encysted cyathostomes: Late L3 and L4 mucosal cyathostome larvae Ascarids: Parascaris equorum: (adults and L4 larval stages) Pinworms: Oxyuris equi: (adults and L4 larval stages) Hairworms: Trichostrongylus axei: (adults) Large-mouth stomach worms: Habronema muscae: (adults) Horse stomach bots: Gasterophilus intestinalis: (2nd and 3rd instars), Gasterophilus nasalis: (3rd instars) One administration of the recommended dose rate of QUEST (moxidectin) 2% Equine Oral Gel also suppresses strongyle egg production through 84 days. QUEST is indicated for use in horses and ponies, including breeding mares and stallions, and foals six months of age and older.

Dosage
0.4 mg moxidectin/ kg body weight
Limitations

QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption.

FDA page: Open in Animal Drugs @ FDA

Species: Horse, Six Months And Older Not For Food
Composition / specifications
Each milliliter of gel contains 20 milligrams (2.0 percent) moxidectin and 125 milligrams (12.5 percent) praziquantel.
Horses and Ponies
Indication
For the treatment and control of large strongyles: Strongylus vulgaris (adults and L4/L5 arterial stages), S. edentatus (adult and tissue stages), Triodontophorus brevicauda (adults), and T. serratus (adults); small strongyles (adults): (Cyathostomum species, including C. catinatum and C. pateratum; Cylicocyclus species, including C. insigne, C. leptostomum, C. nassatus and Cylicocyclus radiatus; Cylicostephanus species, including C. calicatus, C. goldi, C. longibursatus, and C. minutus; Coronocyclus species, including C. coronatus, C. labiatus, and C. labratus; Gyalocephalus capitatus; and Petrovinema poculatus; small strongyles: undifferentiated luminal larvae; encysted cyathostomes (late L3 and L4 mucosal cyathostome larvae); ascarids: Parascaris equorum (adults and L4 larval stages); pinworms: Oxyuris equi (adults and L4 larval stages); hairworms: Trichostrongylus axei (adults); large-mouth stomach worms: Habronema muscae (adults); horse stomach bots: Gasterophilus intestinalis (2nd and 3rd instars) and G. nasalis (3rd instars); and tapeworms: Anoplocephala perfoliata (adults). One dose also suppresses strongyle egg production for 84 days.
Dosage
Administer by mouth as a single dose: 0.4 milligram moxidectin per kilogram and 2.5 milligrams praziquantel per kilogram (2.2 pounds) body weight.
Limitations

For oral use in horses and ponies 6 months of age and older. Do not use in horses intended for human consumption.QUEST PLUS Gel has been formulated specifically for use in horses and ponies only.Reproductive safety studies on breeding stallions have not been conducted.This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result.Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
100 mg/mL (10%) imidacloprid and 25 mg/mL (2.5%) moxidectin
Dogs
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis); for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis; and for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).

Dosage

The recommended minimum dose is 4.5 mg/lb (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Beef And Non-Lactating Dairy
Composition / specifications
10 mg moxidectin/mL
Beef and nonlactating dairy cattle
Indication

For the treatment and control of the following internal and external parasites of cattle:


Gastrointestinal Roundworms
Ostertagia ostertagi – Adults and L4 (including inhibited Larvae)
Haemonchus placei – Adults
Trichostrongylus axei – Adults and L4
Trichostrongylus colubriformis – Adults and L4
Cooperia oncophora – Adults
Cooperia pectinata – Adults
Cooperia punctata – Adults and L4
Cooperia spatulata – Adults
Cooperia surnabada – Adults and L4
Nematodirus helvetianus – Adults
Oesophagostomum radiatum – Adults and L4
Trichuris spp. – Adults
Lungworms
Dictyocaulus viviparus – Adults and L4
Cattle Grubs
Hypoderma bovis
Hypoderma lineatum
Mites
Psoroptes ovis (Psoroptes communis var. bovis)
Lice
Linognathus vituli
Solenopotes capillatus
Persistent Activity: Moxidectin Injectable has been proven to effectively protect cattle from reinfection with Dictyocaulus viviparus and Oesophagostomum radiatum for 42 days after treatment, Haemonchus placei for 35 days after treatment, and Ostertagia ostertagi and Trichostrongylus axei for 14 days after treatment.

Dosage

Administer by subcutaneous injection 1 mL for each 110 lb (50 kg) body weight to provide 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
Each milliliter of solution contains 100 milligrams (mg) imidacloprid and 25 mg moxidectin.
Dogs
Indication
For the prevention of heartworm disease caused by Dirofilaria immitis; and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; and the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis); kills adult fleas and treats flea infestations (Ctenocephalides felis); treats and controls sarcoptic mange caused by Sarcoptes scabiei var. canis.
Dosage
Apply 4.5 mg/lb body weight (10 mg/kg) imidacloprid and 1.1 mg/lb (2.5 mg/kg)moxidectin, once a month.
Limitations

Do not administer this product orally. For the first 30 minutes after application ensure that dogs cannot lick the product from application sites on themselves or other treated animals. Federal Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use this product (containing 2.5 %moxidectin) on cats.

FDA page: Open in Animal Drugs @ FDA

Species: No Use Class Stated Or Implied • Cat, No Use Class Stated Or Implied
Composition / specifications
Each milliliter of solution contains 100 mg imidacloprid and 10 mg moxidectin
Ferrets
Indication
For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.
Dosage
The recommended minimum dose is 9 mg/lb (20 mg/kg) imidacloprid and 0.9 mg/lb (2 mg/kg) moxidectin, once a month, by topical administration.
Limitations
Use only the 0.4 mL ADVANTAGE MULTI for Cats in ferrets. The 0.23 mL size does not provide an effective dose and the 0.8mL size could result in an overdose. Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use on sick or debilitated ferrets. Do not apply to irritated skin.
Cats
Indication
For the prevention of heartworm disease caused by Dirofilaria immitis; for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme); kills adult fleas and treats flea infestations (Ctenocephalides felis).
Dosage

Apply 4.5 mg/lb body weight (10 mg/kg) imidacloprid and 0.45 mg/lb (1.0 mg/kg) moxidectin, once a month.

Limitations
Federal (U.S.A.) Law restricts this drug to use by or on the order of a licensed veterinarian. Do not use on sick, debilitated, or underweight cats. Do not use on cats less than 9 weeks of age or less than 2 lbs. body weight. Do not apply to irritated skin.

FDA page: Open in Animal Drugs @ FDA

Species: Beef • Calves, excluding veal calves • Dairy, not breeding age
Composition / specifications
Each milliliter contains 5 milligrams of moxidectin (0.5 percent solution).
Beef and Dairy Cattle
Indication
For treatment and control of internal and external parasites: gastrointestinal roundworms (Ostertagia ostertagi (adult and L4, including inhibited larvae), Haemonchus placei (adult and L4), Trichostrongylus axei (adult and L4), T. colubriformis (adult and L4), Cooperia oncophora (adult and L4), C. pectinata (adult), C. punctata (adult and L4), C. spatulata (adult), C. surnabada (adult and L4), Bunostomum phlebotomum (adult), Oesophagostomum radiatum (adult and L4), Nematodirus helvetianus (adult and L4)); lungworms (Dictyocaulus viviparus, adult and L4); cattle grubs (Hypoderma bovis, H. lineatum); mites (Chorioptes bovis, Psoroptes ovis (P. communis var. bovis)); lice (Linognathus vituli, Haematopinus eurysternus, Solenopotes capillatus, Bovicola(Damalinia) bovis); and horn flies (Haematobia irritans). To control infections and to protect from reinfection with H. placei for 14 days after treatment, O. radiatum and O. ostertagi for 28 days after treatment, and D. viviparus for 42 days after treatment.
Dosage
The recommended rate of administration is 1 mL for each 22 lb (10 kg) of body weight which provides 5 mg moxidectin for each 22 lb (10 kg) of body weight.
Limitations
A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Excluding Under 6 Months Of Age
Composition / specifications
The drug product consists of two separate vials. One contains 10 percent moxidectin microspheres, and the other contains a vehicle for constitution of the moxidectin microspheres. Each milliliter of constituted, sustained-release suspension contains 3.4 milligrams (mg) of moxidectin.
Dogs
Indication
For treatment of existing larval and adult hookworm (Ancylostoma caninum and Unicinaria stenocephala) infections.
Dosage
0.05 mL of the constituted suspension/kg body weight (0.0227 mL/lb). This amount of suspension will provide 0.17 mg per kilogram body weight (0.0773 mg per pound) as a single subcutaneous injection.
Limitations
Do not administer ProHeart 6 to dogs who are sick, debilitated, underweight or who have a history of weight loss. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. To ensure accurate dosing, calculate each dose based on the dog’s weight at the time of treatment. Do not overdose growing puppies in anticipation of their expected adult weight. No more than 3 mL should be administered in a single site. ProHeart 6 should not be used more frequently than every 6 months. The safety and eff ectiveness of ProHeart 6 has not been evaluated in dogs less than 6 months of age. Caution should be used when administering ProHeart 6 to heartworm positive dogs.
Indication
For prevention of heartworm disease caused by Dirofilaria immitis.
Dosage
0.05 mL of the constituted suspension/kg body weight (0.0227 mL/lb). This amount of suspension will provide 0.17 mg per kilogram body weight (0.0773 mg per pound) as a single subcutaneous injection.
Limitations
Do not administer ProHeart 6 to dogs who are sick, debilitated, underweight or who have a history of weight loss. Federal (U.S.A.) law restricts this drug to use by or on the order of a licensed veterinarian. To ensure accurate dosing, calculate each dose based on the dog’s weight at the time of treatment. Do not overdose growing puppies in anticipation of their expected adult weight. No more than 3 mL should be administered in a single site. ProHeart 6 should not be used more frequently than every 6 months. The safety and eff ectiveness of ProHeart 6 has not been evaluated in dogs less than 6 months of age. Caution should be used when administering ProHeart 6 to heartworm positive dogs.

FDA page: Open in Animal Drugs @ FDA

Species: Sheep, No Use Class Stated Or Implied
Composition / specifications
Each milliliter (mL) of solution contains 1 milligram (mg) moxidectin.
Sheep
Indication
For the treatment and control of the adult and L4 larval stages of Haemonchus contortus, Teladorsagia circumcincta, T. trifurcate, Trichostrongylus axei, T. colubriformis, T. vitrines, Cooperia curticei, C. oncophora, Oesophagostomum columbianum, O. venulosum, Nematodirus battus, N. filicollis, and N. spathiger.
Dosage
Administer 1 mL per 11 pounds body weight (1 mL per 5 kilograms) by mouth.
Limitations
CYDECTIN Oral Drench for Sheep has been formulated specifically for oral use in sheep and should not be given by any other route of administration. Do not use in sick, debilitated, or underweight animals. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result.

FDA page: Open in Animal Drugs @ FDA

Species: Cat, No Use Class Stated Or Implied
Composition / specifications
100 mg/mL (10%) imidacloprid and 10 mg/mL (1%) moxidectin
Cats
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworm (Toxocara cati).

Dosage

The recommended minimum dose is 4.5 mg/lb. (10.0 mg/kg) imidacloprid and 0.45 mg/lb. (1.0 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
100 mg/mL (10%) imidacloprid and 25 mg/mL (2.5%) moxidectin
Dogs
Indication

For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. For the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).

Dosage

The recommended minimum dose is 4.5 mg/lb. (10 mg/kg) imidacloprid and 1.1 mg/lb. (2.5 mg/kg) moxidectin, once a month, by topical administration.

Limitations

FDA page: Open in Animal Drugs @ FDA

Species: Dog, Excluding Under 8 Weeks Age
Composition / specifications
Each tablet contains 30, 68, or 136 micrograms of moxidectin.
Dogs
Indication
To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease.
Dosage
3 micrograms per kilogram (1.36 micrograms per pound) of body weight, once a month.
Limitations
Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Beef • Dairy, excluding female breeding age animals
Composition / specifications
Contains 10 mg moxidectin/mL
Cattle (Beef and Non-Lactating Dairy)
Indication
For treatment and control of gastrointestinal roundworms: Ostertagia ostertagi (adults, fourth-stage larvae, and inhibited larvae), Haemonchus placei (adults), Trichostrongylus axei (adults and fourth-stage larvae), T. colubriformis (adults and fourth-stage larvae), Cooperia oncophora (adults), C. pectinate (adults), C. punctate (adults and fourth-stage larvae), C. spatulata (adults), C. surnabad (adults and fourth-stage larvae), Nematodirus helvetianus (adults), Oesophagostomum radiatum (adults and fourth-stage larvae), Trichuris spp. (adults); lungworms: Dictyocaulus viviparous (adults and fourth-stage larvae); grubs: Hypoderma bovis and H. lineatum; mites: Psoroptes ovis (P. communis var. bovis); lice: Linognathus vituli and Solenopotes capillatus; for protection of cattle from reinfection with D. viviparous and O. radiatum for 42 days after treatment, with H. placei for 35 days after treatment, and with O. ostertagi and T. axei for 14 days after treatment.
Dosage
0.2 mg/kilogram body weight (0.2 mg/2.2 pound) as a single subcutaneous injection.
Limitations
Do not slaughter cattle within 21 days of treatment. Because a withholding time for milk has not been established, do not use in female dairy cattle of breeding age. A withdrawal period has not been established for preruminating calves. Do not use in calves to be processed for veal.

FDA page: Open in Animal Drugs @ FDA

Species: Dog, No Use Class Stated Or Implied
Composition / specifications
2.5% moxidectin
Dogs (Dogs and Puppies At Least 7 Weeks of Age)
Indication
For the prevention of heartworm disease caused by Dirofilaria immitis, and for the treatment and control of Ancylostoma caninum (adults, immature adults, and fourth stage larvae), Uncinaria stenocephala (adults, immature adults, and fourth stage larvae), Toxocara canis (adults and fourth stage larvae), Toxascaris leonina (adults), and Trichuris vulpis (adults) in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 pounds.
Dosage
Administer topically a minimum of 1.1 mg/lb (2.5 mg/kg) of body weight, once monthly using the appropriate pre-loaded applicator tube.
Limitations
Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Official Documents (FDA)

Direct links to FDA-hosted PDFs and SPL packages (when available).

Documents
  • Summary

    This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (longhorned tick) tick infestations for one month in dogs and puppies 8 weeks of age and older, weighing 3.3 pounds or greater, and for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.

  • Summary

    This supplement provides for the addition of the indication for the treatment and control of hookworm (fourth stage larvae, immature adult, and adult Ancylostoma caninum) infections in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater.

  • Summary

    For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina), hookworm (adult Uncinaria stenocephala), and tapeworm (Dipylidium caninum, Taenia pisiformis, and Echinococcus granulosus) infections. Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older, and weighing 3.3 pounds or greater.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    This supplement provides for the addition of the indication for the treatment and control of Amblyomma maculatum (Gulf Coast tick) infestations for 2 months in cats and kittens 6 months of age and older and weighing 2.6 pounds or greater.


  • Summary

    This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (Asian longhorned tick) infestations for 2 months in cats and kittens 6 months of age and older and weighing 2.6 pounds or greater.

  • Summary

    For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment of infections with intestinal roundworm (Toxocara cati, 4th stage larvae, immature adults, and adults) and hookworm (Ancylostoma tubaeforme, 4th stage larvae, immature adults, and adults); kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations (Ixodes scapularis (black-legged tick) and Dermacentor variabilis (American dog tick)) for 2 months in cats and kittens 6 months of age and older and weighing 2.6 lb or greater.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    This supplement provides for the addition of the indication for the treatment and control of Amblyomma maculatum (Gulf Coast tick) infestations for one month in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater.

  • Summary

    This supplement provides for the addition of the indication for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks.

  • Summary

    This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (longhorned tick) infestations in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater, for one month. This supplement also provides for the addition of label language regarding the results of a second flea field study and improvement of erythema, alopecia, papules, scales, crusts, and excoriation in dogs with flea infestations and signs of Flea Allergy Dermatitis following treatment with afoxolaner alone, as a direct result of eliminating fleas.

  • Summary

    For the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of adult hookworm (Ancylostoma caninum, Ancylostoma braziliense, and Uncinaria stenocephala) and roundworm (Toxocara canis and Toxascaris leonina) infections. Kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of Ixodes scapularis (black-legged tick), Rhipicephalus sanguineus (brown dog tick), Dermacentor variabilis (American dog tick), and Amblyomma americanum (lone star tick) infestations for one month in dogs and puppies eight weeks of age and older, weighing four pounds of body weight or greater.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. It is also indicated for the treatment and control of the following intestinal parasites: adult, immature adult and fourth stage larvae in hookworm species (Ancylostoma caninum and Uncinaria stenocephala); adult and fourth stage larvae in roundworm species (Toxocara canis); and adult stage in roundworm species (Toxascaris leonina) and whipworm (Trichuris vulpis).

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    Cats: For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. For the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxocara cati).

    Ferrets: For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenophalides felis) and is indicated for the treatment of flea infestations on ferrets.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    For the prevention of heartworm disease caused by Dirofilaria immitis; and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; and the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis); kills adult fleas and treats flea infestations (Ctenocephalides felis); treats and controls sarcoptic mange caused by Sarcoptes scabiei var. canis.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    This supplement provides for the addition of the indication for the prevention of Dipylidium caninum (tapeworm) infections as a direct result of killing Ctenocephalides felis vector fleas on the treated dog for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater.

  • Summary

    This supplement provides for the addition of the indication for the treatment and control of Haemaphysalis longicornis (Asian longhorned tick) infestations for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater.

  • Summary

    This supplement provides for the addition of the indications, for the prevention of Borrelia burgdorferi infections as a direct result of killing Ixodes scapularis vector ticks and for the treatment and control of L4 and immature adult Ancylostoma caninum.

  • Summary

    Simparica Trio® is indicated for the prevention of heartworm disease caused by Dirofilaria immitis and for the treatment and control of roundworm (immature adult and adult Toxocara canis and adult Toxascaris leonina) and adult hookworm (Ancylostoma caninum and Uncinaria stenocephala) infections. Simparica Trio® kills adult fleas (Ctenocephalides felis) and is indicated for the treatment and prevention of flea infestations, the treatment and control of tick infestations with Amblyomma americanum (lone star tick), Amblyomma maculatum (Gulf Coast tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick), and Rhipicephalus sanguineus (brown dog tick) for one month in dogs and puppies 8 weeks of age and older, and weighing 2.8 pounds or greater.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis); for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis; and for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    Cats: For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme).

    Ferrets: For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    This supplement provides for the addition of the following indications for ferrets: For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

  • Summary

    For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancyclostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxacara cati).

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    This supplement provides for the addition of the following indications for ferrets: For the prevention of heartworm disease in ferrets caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.

  • Summary

    For the prevention of heartworm disease caused by Dirofilaria immitis; kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations, intestinal roundworms (Toxocara cati), and hookworms (Ancylostoma tubaeforme).

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    The supplement provides for the use of moxidectin gel for the treatment and control of adult Cylicocyclus radiatus and Petrovinema poculatus based on results from additional dose confirmation studies.
  • Summary

    For the treatment and control of the following stages of gastrointestinal parasites of horses and ponies six months of age and older which will not to be used for food: Large strongyles: Strongylus vulgaris (adult and L4/L5 arterial stages), Strongylus edentatus (adult and tissue stages), Triodontophorus brevicauda (adults), Triodontophorus serratus (adults) Small strongyles (adults): Cyathostomum spp. including C. catinatum, C. pateratum; Cylicocyclus spp. including C. insigne, C. leptostomum, C. nassatus; Cylicostephanus spp. including C.calicatus, C. goldi, C. longibursatus, C. minutis; Coronocyclus spp., including C. coronatus, C. labiatus, C. labratus; Gyalocephalus capitatus; undifferentiated luminal larvae Encysted cyathostomes: late L3 and L4 mucosal cyathostome larvae Ascarids: Parascaris equorum (adults and L4 larval stages) Pinworms: Oxyuris equi (adults and L4 larval stages) Hairworms: Trichostrongylus axei (adults) Large-mouth stomach worms: Habronema muscae (adults) Horse stomach bots: Gasterophilus intestinalis (2nd and 3rd instars), G. nasalis (3rd instars) One dose also suppresses strongyles egg production for 84 days.

  • Summary
    Raise the minimum age limit for use of this product from 4 months up to 6 months of age.
  • Summary

    a. New indication: For the treatment and control of Gasterophilus nasalis (3rd instars)
    b. Labeling Change: The precautions section is revised to read “This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result.” The photograph on the carton was changed to remove the picture of a young foal.

  • Summary

    dose level of 0.4 mg moxidectin/kg (2.2 lb) body weight, has been demonstrated to be effective in the treatment and control of the following stages of gastrointestinal parasites of horses and ponies:
    Large strongyles: Strongylus vulgaris - (adults and L4/L5 arterial stages), Strongylus edentatus - (adults and tissue stages), Triodontophorus brevicauda - (adults), riodontophorus serratus - (adults)

    Small strongyles (adults and larvae): Cyathostomum spp. - (adults), Cylicocyclus spp. - (adults), Cylicostephanus spp. - (adults), Gyalocephalus capitatus - (adults), Undifferentiated lumenal larvae

    Encysted cyathostomes: Late L3 and L4 mucosal cyathostome larvae

    Ascarids: Parascaris equorum - (adults and L4 larval stages)

    Pin worms: Oxyuris equi - (adults and L4 larval stages)

    Hair worms: Trichostrongylus axei - (adults)

    Large-mouth stomach worms: Habronema muscae - (adults)

    Horse stomach bots: Gasterophilus intestinalis - (2nd & 3rd instars)

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    This supplement supports the safe use in breeding, pregnant, or lactating mares.
  • Summary
    The supplement provides for the use of QUEST Plus gel for the treatment and control of adult Cylicocyclus radiatus and Petrovinema poculatus based on results from additional dose confirmation studies.
  • Summary
    For the treatment and control of the following stages of gastrointestinal parasites of horses and ponies
  • Summary
    For the treatment and control of the following stages of gastrointestinal parasites of horses and ponies six months of age and older and not to be used for food
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs; kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis); for the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis; and for the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    This supplement provides for the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs and the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis.
  • Summary
    ADVANTAGE MULTI for Dogs is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. ADVANTAGE MULTI for Dogs kills adult fleas and is indicated for the treatment of flea infestations ( Ctenocephalides felis). ADVANTAGE MULTI for Dogs is also indicated for the treatment and control of the following intestinal parasites:
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    This supplement provides for the prevention of heartworm disease in ferrets caused by Dirofilaria immitis; kills adult fleas ( Ctenocephalides felis) and is indicated for the treatment of flea infestations on ferrets.
  • Summary
    ADVANTAGE MULTI for Cats is indicated for the prevention of heartworm disease caused by Dirofilaria immitis. ADVANTAGE MULTI for Cats kills adult fleas ( Ctenocephalides felis) and is indicated for the treatment of flea infestations. ADVANTAGE MULTI for Cats is also indicated for the treatment and control of ear mite ( Otodectes cynotis) infestations and the following intestinal parasites:
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    This supplemental application provides for treatment and control of infections of additional life stages and species of gastrointestinal roundworms for topical use of 0.5% moxidectin solution on cattle.
  • Summary
    This supplemental application provides for topical use of a 0.5% moxidectin solution on dairy cattle of breeding age for treatment and control of infections and infestations of certain internal and external parasites. In addition, the regulations are amended to establish a tolerance for moxidectin residues in milk.
  • Summary
    Effective in the treatment and control of external parasites. CYDECTIN® (moxidectin) 0.5% Pour-On for Cattle has been proven to effectively control infections and to protect cattle from reinfection with Ostertagia ostertagi for 28 days following treatment and Dictyocaulus viviparus for 42 days after treatment.
  • EA 141-099
  • FONSI 141-099
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    This supplement provides for the revision of the animal safety information in the warning, precaution, adverse reactions, and post-approval sections of the product labeling.
  • Summary
    New indication for the treatment of existing larval and adult hookworm ( Uncinaria stenocephala) infections.
  • Summary
    For the prevention of heartworm disease caused by Dirofilaria immitis and for treatment of existing larval and adult hookworm (Ancylostoma caninum) infections.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    CYDECTIN Oral Drench for Sheep, when administered at the recommended dose of 0.2 mg moxidectin/2.2 lb (0.2 mg/kg) body weight (BW), is effective in the treatment and control of the adult and larval (L4) stages of the following internal parasites of sheep:
    Haemonchus contortus - Adult and L4 larvae
    Teladorsagia circumcincta – Adult and L4 larvae
    Teladorsagia trifurcata - Adult and L4 larvae
    Trichostrongylus axei - Adult and L4 larvae
    Trichostrongylus colubriformis - Adult and L4 larvae
    Trichostrongylus vitrinus – Adult and L4 larvae
    Cooperia curticei - Adult and L4 larvae
    Cooperia oncophora – Adult and L4 larvae
    Oesophagostomum columbianum - Adult and L4 larvae
    Oesophagostomum venulosum – Adult and L4 larvae
    Nematodirus battus - Adult and L4 larvae
    Nematodirus filicollis - Adults and L4 larvae
    Nematodirus spathiger - Adults and L4 larvae

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    For the prevention of heartworm disease caused by Dirofilaria immitis. Kills adult fleas (Ctenocephalides felis) and is indicated for the treatment of flea infestations. It is also indicated for the treatment and control of ear mite (Otodectes cynotis) infestations and the following intestinal parasites: adult, immature adult, and fourth stage larvae in hookworms (Ancylostoma tubaeforme); and adult and fourth stage larvae in roundworms (Toxocara cati).

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    For the prevention of heartworm disease caused by Dirofilaria immitis and the treatment of Dirofilaria immitis circulating microfilariae in heartworm-positive dogs. Kills adult fleas and is indicated for the treatment of flea infestations (Ctenocephalides felis). For the treatment and control of sarcoptic mange caused by Sarcoptes scabiei var. canis. For the treatment and control of intestinal roundworms (Toxocara canis and Toxascaris leonina), hookworms (Ancylostoma caninum and Uncinaria stenocephala), and whipworms (Trichuris vulpis).

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    ProHeart (moxidectin) heartworm prevention tablets are indicated for once-a-month use in dogs to prevent infections by the canine heartworm, Dirofilaria immitis, and the subsequent development of canine heartworm disease.

SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary

    Addition of six new therapeutic claims:
    Trichostrongylus colubriformis – Adult
    Cooperia pectinata – Adult
    Cooperia spatulata – Adult
    Nematodirus helvetianus – Adult
    Ostertagia ostertagi – L4
    Trichostrongylus axei – L4

  • Summary
    CYDECTIN Injectable when administered at the recommended dose level of 0.2 mg/2.2 lb (0.2 mg/kg) body weight is effective in the treatment and control of the following internal and external parasites of cattle:
  • EA 141-220
  • FONSI 141-220
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Documents
  • Summary
    For the prevention of heartworm disease caused by Dirofilaria immitis, and for the treatment and control of Ancylostoma caninum (adults, immature adults, and fourth stage larvae), Uncinaria stenocephala (adults, immature adults, andfourth stage larvae), Toxocara canis (adults and fourth stage larvae), Toxascaris leonina (adults), and Trichuris vulpis (adults) in dogs and puppies that are at least 7 weeks of age and that weigh at least 3 pounds.
SPL Packages

FDA page: Open in Animal Drugs @ FDA

Usage

To prevent infection by the canine heartworm Dirofilaria immitis and the subsequent development of canine heartworm disease. For the treatment and control of the following stages of gastrointestinal parasites in horses and ponies: Large Strongyles : Strongylus vulgaris : (adults and L4 / L5 arterial stages), Strongylus edentatus : (adults and tissue stages), Triodontophorus brevicauda : (adults), Triodontophorus serratus : (adults) Small Strongyles (adults): Cyathostomum spp., including Cyathostomum catinatum , Cyathostomum pateratum Cylicostephanus spp., including Cylicostephanus calicatus , Cylicostephanus goldi , Cylicostephanus longibursatus , Cylicostephanus minutus Cylicocyclus spp., including Cylicocyclus insigne , Cylicocyclus leptostomum , Cylicocyclus nassatus , Cylicocyclus radiatus Coronocyclus spp., including Coronocyclus coronatus , Coronocyclus labiatus , Coronocyclus labratus , Gyalocephalus capitatus , Petrovinema poculatus Small Strongyles : Undifferentiated lumenal larvae Encysted cyathostomes : Late L3 and L4 mucosal cyathostome larvae Ascarids : Parascaris equorum : (adults and L4 larval stages) Pinworms : Oxyuris equi : (adults and L4 larval stages) Hairworms : Trichostrongylus axei : (adults) Large-mouth stomach worms : Habronema muscae : (adults) Horse stomach bots : Gasterophilus intestinalis : (2nd and 3rd instars), Gasterophilus nasalis : (3rd instars) One administration of the recommended dose rate of QUEST (moxidectin) 2% Equine Oral Gel also suppresses strongyle egg production through 84 days. QUEST is indicated for use in horses and ponies, including breeding mares and stallions, and foals six months of age and older. For treatment and control of internal and external parasites: gastrointestinal roundworms ( Ostertagia ostertagi (adult and L4, including inhibited larvae), Haemonchus placei (adult and L4), Trichostrongylus axei (adult and L4), T. colubriformis (adult and L4), Cooperia oncophora (adult and L4), C. pectinata (adult), C. punctata (adult and L4), C. spatulata (adult), C. surnabada (adult and L4), Bunostomum phlebotomum (adult), Oesophagostomum radiatum (adult and L4), Nematodirus helvetianus (adult and L4)); lungworms ( Dictyocaulus viviparus , adult and L4); cattle grubs ( Hypoderma bovis , H. lineatum ); mites ( Chorioptes bovis , Psoroptes ovis ( P. communis var. bovis )); lice ( Linognathus vituli , Haematopinus eurysternus , Solenopotes capillatus , Bovicola ( Damalinia ) bovis ); and horn flies ( Haematobia irritans ). To control infections and to protect from reinfection with H. placei for 14 days after treatment, O. radiatum and O. ostertagi for 28 days after treatment, and D. viviparus for 42 days after treatment.

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

Use once-a-month in dogs at 8 weeks of age or older. Federal law restricts this drug to use by or on the order of a licensed veterinarian. QUEST 2% Equine Oral Gel has been formulated specifically for use in horses and ponies only. This product should not be used in other animal species as severe adverse reactions, including fatalities in dogs, may result. Extreme caution should be used when administering the product to foals, young and miniature horses, as overdosage may result in serious adverse reactions. Do not use in sick, debilitated, or underweight animals. Do not use in horses intended for human consumption. A withdrawal period has not been established for this product on preruminating calves. Do not use on calves to be processed for veal.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite • Cat

Showing top 5 for Digestive.

Skin & allergy
Localised itching (1) • Cat Localised hair loss (1) • Cat Hair loss NOS (1) • Cat Chewing - pruritus (1) • Cat Hair loss at application site • Cat
Show more (1)
Application site hair loss • Cat

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking • Dog

Showing top 5 for Neurologic.

Behavior
Biting -aggression (1) • Cat Behavioral disorder (1) • Cat

Showing top 5 for Behavior.

Effectiveness
Lack of efficacy (endoparasite) - tapeworm (1) • Dog Lack of efficacy (endoparasite) - hookworm (1) • Dog Lack of efficacy (endoparasite) - heartworm (1) • Dog Lack of efficacy (ectoparasite) - flea (1) • Dog

Showing top 5 for Effectiveness.

Other
Skin sore (1) • Cat Skin lesion NOS (1) • Cat Skin irritation (1) • Dog Skin discolouration NOS (1) • Cat Scratching (1) • Cat
Show more (13)
Rubbing (1) • Cat Rolling (1) • Cat Reddening of the skin (1) • Dog Medication error NOS (1) • Dog Loose stool (1) • Dog Licking at application site (1) • Cat Intentional misuse (1) • Dog Foaming at the mouth (1) • Cat Diabetes (1) • Cat Death (1) • Cat Anaphylaxis • Dog Abnormal radiograph finding • Dog Abnormal movement NOS • Dog

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Crossbred Canine/dog, Male, 4 year, 33.112 kilogram • Drug: MSK, Suspension, Subcutaneous • Reactions: Lack of efficacy (endoparasite) - heartworm • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-056101
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Male
  • Age: 4.00 Year
  • Weight: 33.112 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Suspension
Reactions Reported:
Lack of efficacy (endoparasite) - heartworm
Outcomes: Ongoing

Dog, Spaniel - Cocker American, Male, 2.83 year, 10.43 kilogram • Drug: MSK, Solution, Topical, Dose: 1 tube per animal • Reactions: Loose stool, Lack of efficacy (ectoparasite) - flea • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-055969
  • Serious AE: No
  • Treated For AE: No
  • Sex: Male
  • Age: 2.83 Year
  • Weight: 10.430 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Topical
  • Form: Solution
  • Dose: 1 tube per animal
Reactions Reported:
Loose stool Lack of efficacy (ectoparasite) - flea
Outcomes: Outcome Unknown

Dog, Terrier - Bull - American Pit, Female, 3 year, 22.77 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 1.20 mL per animal • Reactions: Lack of efficacy (endoparasite) - heartworm • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055331
  • Serious AE: Yes
  • Treated For AE: No
  • Sex: Female
  • Age: 3.00 Year
  • Weight: 22.770 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Suspension
  • Dose: 1.20 mL per animal
Reactions Reported:
Lack of efficacy (endoparasite) - heartworm
Outcomes: Ongoing

Dog, Shih Tzu, Female, 3 year, 4.98 kilogram • Drug: MSK, Solution, Topical • Reactions: Reddening of the skin, Skin irritation • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-055994
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 3.00 Year
  • Weight: 4.980 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Topical
  • Form: Solution
Reactions Reported:
Reddening of the skin Skin irritation
Outcomes: Outcome Unknown

Dog, ['Shepherd (unspecified)', 'Dog (unknown)'], Male, 14 month, 26.762 kilogram • Drug: MSK, Solution, Unknown • Reactions: Lack of efficacy (endoparasite) - heartworm • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055791
  • Serious AE: No
  • Treated For AE: Yes
  • Sex: Male
  • Age: 14.00 Month
  • Weight: 26.762 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Solution
Reactions Reported:
Lack of efficacy (endoparasite) - heartworm
Outcomes: Ongoing

Dog, Bulldog - French, Female, 2 year, 13.608 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 0.72 mL per animal • Reactions: Lack of efficacy (endoparasite) - hookworm • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-054879
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 2.00 Year
  • Weight: 13.608 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Suspension
  • Dose: 0.72 mL per animal
Reactions Reported:
Lack of efficacy (endoparasite) - hookworm
Outcomes: Ongoing

Dog, ['Spaniel - Cocker American', 'Poodle (unspecified)'], Male, 10 year, 4.491 kilogram • Drug: MSK, Suspension, Subcutaneous, Dose: 0.23 mL per animal, Frequency: 1 per year • Reactions: Lack of efficacy (endoparasite) - hookworm • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-055178
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 10.00 Year
  • Weight: 4.491 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Subcutaneous
  • Form: Suspension
  • Dose: 0.23 mL per animal
  • Frequency: 1 per year
Reactions Reported:
Lack of efficacy (endoparasite) - hookworm
Outcomes: Ongoing

Cat, Domestic Shorthair, Female, 2 year, 3.63 kilogram • Drug: MSK, Solution, Topical, Dose: 1 tube per animal • Reactions: Foaming at the mouth, Licking at application site • Outcome: Recovered/Normal

  • Report ID: USA-USFDACVM-2025-US-055996
  • Serious AE: No
  • Treated For AE: No
  • Sex: Female
  • Age: 2.00 Year
  • Weight: 3.630 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Topical
  • Form: Solution
  • Dose: 1 tube per animal
Reactions Reported:
Foaming at the mouth Licking at application site
Outcomes: Recovered/Normal

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.